Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 9 Parkinson's papers of 3,909 | 0.70 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2824
Sealed predictions
- TET2 in dopamine neurons, braak+0.29 (p 0.456) → +0.88 (p 0.002)receipt 2831
Swarm cases
receipt 2831: TET2 in dopamine neurons, braak
- power
- full sample +0.63 (p 0.0055, n 18), 95% CI +0.22 to +0.85. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.62 (p 0.0064, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.62 (p 0.0064, n 18). not the mix.
- skeptic
- leave-one-out range +0.59 to +0.83, sign flips 0; without severely affected donors +0.63 (p 0.0055, n 18). robust.
- cell type
- strongest in OPCs: +0.66 (p 0.0030, n 18) vs +0.63 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TET2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up TET2 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.15 p 0.594 (needs p < 6.5e-4)
Receipts
loading the receipts